Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Rubicon Research is a Thane-based pharmaceutical formulations company developing and manufacturing specialty and complex generic products primarily for the US market, including drug-device combinations and differentiated dosage forms, with an R&D-led ANDA pipeline. It was backed by General Atlantic prior to its 2025 listing.
Rubicon Research Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Rubicon Research Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 |
|---|---|
| EPS (basic, ₹) | 15.52 |
| Book value / share (₹) | 78.07 |
| Return on equity | 19.1% |
| Return on capital employed | 23.8% |
| Operating margin | 20.2% |
| Net margin | 14.1% |
| EBITDA | ₹400 Cr |
| Free cash flow | ₹-24 Cr |
| Total debt | ₹259 Cr |
| Debt to equity | 0.20 |
| Interest coverage | 8.4 |
| Current ratio | 2.01 |
| Shares outstanding | 16,50,90,000 |
Open the full income statement, balance sheet and cash flow for RUBICON →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.